PARIS Bleeding Risk Score Calculator

PARIS Bleeding Risk Score: Comprehensive Explanation and Clinical Context The PARIS Bleeding Risk Score is a validated clinical tool developed to estimate the risk of major bleeding in patients undergoing dual antiplatelet therapy after percutaneous coronary intervention. It incorporates simple bedside variables that reflect age related vulnerability, hemodynamic reserve, underlying comorbidities, and previous bleeding events. The model stratifies patients into low, intermediate, and high risk groups, which can assist clinicians with individualized decision making related to the duration and intensity of antiplatelet therapy.

This score was derived from a large prospective observational registry and has been externally validated in multiple cohorts. The variables included in the score have strong pathophysiological relevance. Advanced age contributes to frailty, altered drug metabolism, and increased susceptibility to bleeding complications.

Low body mass index may reflect limited physiologic reserve and is associated with increased antithrombotic drug exposure. A prior major bleeding event is one of the strongest predictors of recurrent bleeding. Ongoing anticoagulation therapy significantly increases bleeding risk when combined with dual antiplatelet therapy.

Renal dysfunction impairs drug clearance and alters platelet function, while anemia often reflects chronic disease, reduced tolerance for blood loss, and an increased likelihood of transfusion. Together, these parameters create a clinically intuitive risk model that is practical for routine use. Clinical interpretation should always integrate the therapeutic context.

A low PARIS bleeding score indicates that continuation of standard dual antiplatelet therapy is generally safe. Intermediate scores require thoughtful assessment of competing ischemic and bleeding risks, especially in patients with complex coronary anatomy or prior thrombosis. High risk patients may benefit from shortened duration of dual antiplatelet therapy or the use of safer antiplatelet agents, depending on their ischemic burden and procedural characteristics.

The PARIS score is not intended to replace clinical judgment but rather to complement guideline directed strategies for personalized antithrombotic management. References Costa F et al. Development and validation of a bleeding risk prediction model for patients undergoing coronary stent implantation.

European Heart Journal. 2015. 36:3324 to 3333.

Valgimigli M et al. ESC Focused Update on dual antiplatelet therapy in coronary artery disease. European Heart Journal.

2018. 39:213 to 260. Bhatt DL et al.

Antithrombotic therapy after coronary stenting. New England Journal of Medicine. 2022.

387:245 to 257.